These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36470801)

  • 1. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
    Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
    Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
    Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
    Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
    J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    Switalla KM; Boughey JC; Dimitroff K; Yau C; Ladores V; Yu H; Tchou J; Golshan M; Ahrendt G; Postlewait LM; Piltin M; Reyna CR; Matsen CB; Tuttle TM; Wallace AM; Arciero CA; Lee MC; Tseng J; Son J; Rao R; Sauder C; Naik A; Howard-McNatt M; Lancaster R; Norwood P; Esserman LJ; Mukhtar RA
    Ann Surg Oncol; 2024 Oct; 31(11):7249-7259. PubMed ID: 38995451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Damin AP; Zancan M; Melo MP; Biazus JV
    Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy.
    Dux J; Habibi M; Malik H; Jacobs L; Wright PA; Lange J; Camp M; O'Donnell M; Sun B; Tran HT; Euhus D
    Breast Cancer Res Treat; 2023 Nov; 202(2):267-273. PubMed ID: 37531016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.
    Lim SZ; Yoo TK; Lee SB; Kim J; Chung IY; Ko BS; Lee JW; Son BH; Ahn SH; Kim S; Kim HJ
    Breast Cancer Res Treat; 2024 Jan; 203(1):95-102. PubMed ID: 37796365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
    Chun JW; Kim J; Chung IIY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Breast Cancer Res Treat; 2021 Jun; 187(3):647-655. PubMed ID: 33966181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy.
    Yilmaz L; Kus T; Aytekin A; Aktas G; Uzun E; Maralcan G
    BMC Surg; 2024 Jul; 24(1):213. PubMed ID: 39030524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
    Montagna G; Mrdutt MM; Sun SX; Hlavin C; Diego EJ; Wong SM; Barrio AV; van den Bruele AB; Cabioglu N; Sevilimedu V; Rosenberger LH; Hwang ES; Ingham A; Papassotiropoulos B; Nguyen-Sträuli BD; Kurzeder C; Aybar DD; Vorburger D; Matlac DM; Ostapenko E; Riedel F; Fitzal F; Meani F; Fick F; Sagasser J; Heil J; Karanlik H; Dedes KJ; Romics L; Banys-Paluchowski M; Muslumanoglu M; Perez MDRC; Díaz MC; Heidinger M; Fehr MK; Reinisch M; Tukenmez M; Maggi N; Rocco N; Ditsch N; Gentilini OD; Paulinelli RR; Zarhi SS; Kuemmel S; Bruzas S; di Lascio S; Parissenti TK; Hoskin TL; Güth U; Ovalle V; Tausch C; Kuerer HM; Caudle AS; Boileau JF; Boughey JC; Kühn T; Morrow M; Weber WP
    JAMA Oncol; 2024 Jun; 10(6):793-798. PubMed ID: 38662396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary Axillary Surgical Management in Patients with Pathologically Node Positive Disease After Neoadjuvant Chemotherapy: A Survey of Members of the American Society of Breast Surgeons.
    Weiss A; Colugnati F; Mitchell M; Li Y; Marin C; Gergelis KR; O'Sullivan CC; Boughey JC
    Ann Surg Oncol; 2024 Oct; 31(11):7362-7371. PubMed ID: 38976157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
    Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
    Breast J; 2022; 2022():1507881. PubMed ID: 36051467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy.
    Almahariq MF; Levitin R; Quinn TJ; Chen PY; Dekhne N; Kiran S; Desai A; Benitez P; Jawad MS; Gustafson GS; Dilworth JT
    Ann Surg Oncol; 2021 Feb; 28(2):930-940. PubMed ID: 32712895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.